The subject invention provides novel methods for treating B cell malignancies, such as multiple myeloma, using a combination therapy. Said treatment in accordance with the subject invention comprises the administration of a B cell regulator, e.g., a galectin molecule, to a subject suffering from a B cell malignancy, and wherein said subject received, receives, or will receive a treatment with a conventional treatment for such B cell malignancy, e.g., immunotherapy. The administration of the galectin molecule boosts the expression of B cell specific antigens e.g., SLAMF7, on MM cells, thereby increasing the sensitivity of MM cells to anti-SLAMF7 Ab and therapeutic efficacy of Elotuzumab.

The subject invention provides novel methods for treating B cell malignancies, such as multiple myeloma, using a combination therapy. Said treatment in accordance with the subject invention comprises the administration of a B cell regulator, e.g., a galectin molecule, to a subject suffering from a B cell malignancy, and wherein said subject received, receives, or will receive a treatment with a conventional treatment for such B cell malignancy, e.g., immunotherapy. The administration of the galectin molecule boosts the expression of B cell specific antigens e.g., SLAMF7, on MM cells, thereby increasing the sensitivity of MM cells to anti-SLAMF7 Ab and therapeutic efficacy of Elotuzumab.

The present invention addresses the problem of providing an endocytosis enhancer comprising associates formed from a fluorescent protein. The fluorescent protein is preferably any one selected from the group consisting of a white fluorescent protein, a red fluorescent protein, a yellow fluorescent protein, a blue fluorescent protein and a green fluorescent protein. The endocytosis enhancer according to the present invention can enhance the cellular uptake of a drug, which is encapsulated in micelles each formed from a fluorescent-protein-supported carbosilane dendrimer, through endocytosis.

A TFF2 protein and an IFN-κ protein are combined to treat a novel coronavirus infection. A product comprises: (a) an IFN-κ protein; (b) a TFF2 protein; and (c) an optional pharmaceutically acceptable carrier. Provided are an application of a combination of IFN-κ protein and TFF2 protein in the preparation of a product for the treatment of a novel coronavirus infection and related diseases, and a method for using the product to treat a novel coronavirus infection and related diseases. The foregoing combination, application, and method have excellent therapeutic effects on novel coronavirus infections, and have application prospects and social benefits.

Limb-girdle muscular dystrophy type 2B (LGMD2B) is caused by mutations in the dysferlin gene, resulting in non-functional dysferlin, a key protein found in muscle membrane. Treatment options available for patients are chiefly palliative in nature and focus on maintaining ambulation. A method of treating LGMD2B is disclosed herein. The method includes administering to a patient a suitable amount of a galectin protein or fragment thereof. Treatment with a recombinant galectin promoted myogenic maturation as indicated through improvements in size, myotube alignment, myoblast migration, and membrane repair capacity in dysferlin-deficient myo tubes, explant myofibers and mice.

Provided herein are chemical compounds, methods for their discovery, and their therapeutic and research use. Further provided herein are antiviral and antimicrobial lectin compounds and methods of their use.

The object of the present invention is to provide an aggregatable carrier material for drug delivery system and a micelle formed thereof. The present invention provides an aggregatable carrier material for drug delivery system, which is formed by utilizing the reaction between thiol group and alkyl halide. It is formed by using carbosilane dendrimers containing silole and labeled proteins such as green fluorescent protein in aqueous solvent or in mixed solvent of the aqueous solvent and organic solvent. The micelle composed of the material may incorporate compounds having a variety of molecular weight and biopolymers in the aqueous solvent.

The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteasome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.

The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteasome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.

The present invention provides a method of inducing hair follicle neogenesis in the skin of a subject in need by transplanting the mixture of the skin extract or the composition with epidermal cells or fibroblasts into the subject. The skin extract of the present invention is obtained by mincing and mixing a skin tissue with phosphate buffer solution, thawing the skin tissue after freeze. The composition of the present invention includes at least lumican, galectin-1 and apolipoprotein A-I.